Inspire Medical Systems, Inc. $INSP Stake Lifted by Wasatch Advisors LP

Wasatch Advisors LP boosted its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 19.4% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 138,603 shares of the company’s stock after purchasing an additional 22,535 shares during the period. Wasatch Advisors LP’s holdings in Inspire Medical Systems were worth $7,149,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. CWM LLC grew its position in shares of Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after acquiring an additional 242 shares during the last quarter. Havemeyer Place LP bought a new stake in Inspire Medical Systems in the 4th quarter valued at about $39,000. V Square Quantitative Management LLC acquired a new position in Inspire Medical Systems during the 4th quarter valued at about $40,000. Smartleaf Asset Management LLC boosted its stake in Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after purchasing an additional 205 shares during the period. Finally, Larson Financial Group LLC grew its position in Inspire Medical Systems by 21,266.7% in the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after purchasing an additional 638 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Evercore lowered shares of Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 price target on the stock. in a research note on Tuesday, June 23rd. Royal Bank Of Canada downgraded Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a research report on Monday, June 15th. Wells Fargo & Company decreased their price objective on Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a report on Tuesday, May 5th. JPMorgan Chase & Co. lowered their target price on Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Finally, Zacks Research downgraded Inspire Medical Systems from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 13th. Four research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $81.05.

Inspire Medical Systems Trading Up 5.1%

INSP stock opened at $45.65 on Friday. The firm’s 50-day moving average is $45.52 and its two-hundred day moving average is $65.66. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 4.63 and a beta of 0.73. Inspire Medical Systems, Inc. has a 52 week low of $38.91 and a 52 week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. During the same period last year, the company posted $0.10 EPS. The firm’s quarterly revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, equities research analysts predict that Inspire Medical Systems, Inc. will post 0.93 earnings per share for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.